AKYA vs. SEER, PRLD, ATHA, BNGO, PRE, STRO, NAUT, TELA, SYRS, and ELMD
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Seer (SEER), Prelude Therapeutics (PRLD), Athira Pharma (ATHA), Bionano Genomics (BNGO), Prenetics Global (PRE), Sutro Biopharma (STRO), Nautilus Biotechnology (NAUT), TELA Bio (TELA), Syros Pharmaceuticals (SYRS), and Electromed (ELMD). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Akoya Biosciences has a net margin of -72.68% compared to Seer's net margin of -529.52%. Seer's return on equity of -20.69% beat Akoya Biosciences' return on equity.
In the previous week, Akoya Biosciences had 19 more articles in the media than Seer. MarketBeat recorded 20 mentions for Akoya Biosciences and 1 mentions for Seer. Seer's average media sentiment score of 0.05 beat Akoya Biosciences' score of -0.44 indicating that Seer is being referred to more favorably in the news media.
Akoya Biosciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by company insiders. Comparatively, 15.0% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Akoya Biosciences presently has a consensus target price of $7.79, indicating a potential upside of 173.18%. Seer has a consensus target price of $7.00, indicating a potential upside of 231.75%. Given Seer's higher possible upside, analysts clearly believe Seer is more favorable than Akoya Biosciences.
Summary
Akoya Biosciences beats Seer on 9 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
